Harbour Investments Inc. lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 5,548.3% during the third quarter, Holdings Channel.com reports. The fund owned 18,357 shares of the biotechnology company’s stock after acquiring an additional 18,032 shares during the period. Harbour Investments Inc.’s holdings in Biogen were worth $4,146,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Biogen in the 2nd quarter valued at approximately $3,453,878,000. Primecap Management Co. CA purchased a new stake in Biogen during the 2nd quarter worth approximately $3,274,304,000. Russell Investments Group Ltd. grew its position in Biogen by 1,524.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after purchasing an additional 2,041,161 shares during the last quarter. Legal & General Group Plc acquired a new position in Biogen during the 2nd quarter valued at approximately $322,640,000. Finally, Danske Bank A S increased its stake in Biogen by 1,955.2% during the 3rd quarter. Danske Bank A S now owns 1,363,909 shares of the biotechnology company’s stock valued at $308,080,000 after purchasing an additional 1,297,544 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have issued reports on BIIB. Weiss Ratings cut shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, October 29th. Citigroup reissued a “neutral” rating on shares of Biogen in a report on Wednesday, October 28th. Robert W. Baird boosted their price objective on shares of Biogen from $250.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Stifel Nicolaus set a $242.00 target price on Biogen in a research report on Thursday, September 10th. Finally, Morgan Stanley raised their target price on Biogen from $231.00 to $238.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $254.41.
Check Out Our Latest Research Report on Biogen
Biogen Price Performance
Shares of NASDAQ:BIIB opened at $251.65 on Tuesday. Biogen Inc. has a twelve month low of $160.36 and a twelve month high of $261.00. The company’s 50 day moving average is $233.96 and its 200 day moving average is $205.42. The company has a current ratio of 1.95, a quick ratio of 1.37 and a debt-to-equity ratio of 0.39. The company has a market cap of $37.20 billion, a PE ratio of 107.54, a price-to-earnings-growth ratio of 2.84 and a beta of 0.10.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same period last year, the firm posted $4.81 EPS. Biogen’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, sell-side analysts forecast that Biogen Inc. will post 12.46 EPS for the current year.
Biogen Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Further Reading
- Five stocks we like better than Biogen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
